PT Phapros, Tbk (PEHA.JK)
IDR 280.0
(0.72%)
IDR 280.0
(0.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 71.32 Billion IDR | -32.44% |
| 2022 | 98.77 Billion IDR | 7.24% |
| 2021 | 92.1 Billion IDR | -41.9% |
| 2020 | 158.52 Billion IDR | -17.72% |
| 2019 | 192.65 Billion IDR | -0.54% |
| 2018 | 193.71 Billion IDR | 3.37% |
| 2017 | 187.39 Billion IDR | 45.48% |
| 2016 | 128.81 Billion IDR | 38.76% |
| 2015 | 92.83 Billion IDR | 29.71% |
| 2014 | 71.56 Billion IDR | 7.99% |
| 2013 | 66.27 Billion IDR | -21.94% |
| 2012 | 84.89 Billion IDR | 0.38% |
| 2011 | 84.57 Billion IDR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -13.48 Billion IDR | 30.07% |
| 2024 Q3 | -9.3 Billion IDR | 31.02% |
| 2024 Q1 | -19.28 Billion IDR | -145.26% |
| 2023 Q3 | -11.19 Billion IDR | -150.89% |
| 2023 Q2 | 21.99 Billion IDR | 18.32% |
| 2023 Q1 | 18.58 Billion IDR | -43.85% |
| 2023 Q4 | 42.61 Billion IDR | 480.73% |
| 2023 FY | 66.72 Billion IDR | -32.44% |
| 2022 FY | 98.77 Billion IDR | 7.24% |
| 2022 Q3 | 22.78 Billion IDR | -5.15% |
| 2022 Q2 | 24.02 Billion IDR | 27.45% |
| 2022 Q1 | 18.85 Billion IDR | 0.87% |
| 2022 Q4 | 33.1 Billion IDR | 45.25% |
| 2021 Q1 | 33.31 Billion IDR | 42.32% |
| 2021 FY | 92.1 Billion IDR | -41.9% |
| 2021 Q4 | 18.69 Billion IDR | 43.93% |
| 2021 Q3 | 12.98 Billion IDR | -32.32% |
| 2021 Q2 | 19.18 Billion IDR | -42.4% |
| 2020 Q4 | 23.4 Billion IDR | 311.98% |
| 2020 FY | 158.52 Billion IDR | -17.72% |
| 2020 Q1 | 33.97 Billion IDR | -40.82% |
| 2020 Q2 | 26.73 Billion IDR | -21.3% |
| 2020 Q3 | 5.68 Billion IDR | -78.75% |
| 2019 Q3 | 25.22 Billion IDR | -64.68% |
| 2019 Q4 | 57.4 Billion IDR | 127.57% |
| 2019 FY | 192.65 Billion IDR | -0.54% |
| 2019 Q2 | 71.42 Billion IDR | 321.97% |
| 2019 Q1 | 16.92 Billion IDR | -68.68% |
| 2018 Q4 | 54.04 Billion IDR | -15.74% |
| 2018 Q1 | 16.49 Billion IDR | -79.49% |
| 2018 Q2 | 59.01 Billion IDR | 257.74% |
| 2018 FY | 193.71 Billion IDR | 3.37% |
| 2018 Q3 | 64.14 Billion IDR | 8.69% |
| 2017 Q4 | 80.42 Billion IDR | 0.0% |
| 2017 FY | 187.39 Billion IDR | 45.48% |
| 2016 FY | 128.81 Billion IDR | 38.76% |
| 2015 FY | 92.83 Billion IDR | 29.71% |
| 2014 FY | 71.56 Billion IDR | 7.99% |
| 2013 FY | 66.27 Billion IDR | -21.94% |
| 2012 FY | 84.89 Billion IDR | 0.38% |
| 2011 FY | 84.57 Billion IDR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| PT Darya-Varia Laboratoria Tbk | 190.05 Billion IDR | 62.473% |
| PT Merck Tbk | 199.72 Billion IDR | 64.291% |
| PT Pyridam Farma Tbk | 1.87 Billion IDR | -3694.683% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | 1190.87 Billion IDR | 94.011% |
| PT Tempo Scan Pacific Tbk | 1257.95 Billion IDR | 94.33% |